You are here

  • Home
  • Archive
  • Volume 11, Issue 4
  • Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancerCommentary

Article Text

Article menu
Download PDFPDF
Treatment
Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancer

https://doi.org/10.1136/ebn.11.4.117

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    E A Akl

    Dr E A Akl, State University of New York at Buffalo, Buffalo, NY, USA; elieakl@buffalo.edu

    QUESTION

    In patients with cancer and venous thromboembolism (VTE), is long-term treatment with low-molecular-weight heparin (LMWH) effective and safe compared with oral anticoagulants?

    REVIEW SCOPE

    Studies selected compared LMWH with oral anticoagulants (vitamin K antagonists or ximelagatran) for long-term treatment in patients with cancer and objectively diagnosed VTE. Outcomes were mortality, symptomatic recurrent VTE, major bleeding, and thrombocytopenia.

    REVIEW METHODS

    Cochrane Central Register of Controlled Trials, Medline, EMBASE/Excerpta Medica, and ISI the Web of Science (to Jan 2007); conference proceedings; reference lists; and the “related articles” feature of PubMed were searched for randomised controlled trials (RCTs). …

    View Full Text

    Footnotes

    • Source of funding: no external funding.